WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) announced positive interim results from the AMPLIFY Phase III trial, showing a fixed duration of its drug CALQUENCE® (acalabrutinib) combined with venetoclax, with or without obinutuzumab, significantly improved progression-free survival (PFS) compared to the standard chemoimmunotherapy in untreated chronic lymphocytic leukemia (CLL) patients.
The study, which included adult participants who had not undergone previous treatment, revealed a favorable trend in overall survival (OS) for patients receiving the CALQUENCE combination versus the standard chemoimmunotherapy. However, complete OS data are not yet available, and the trial will continue to evaluate this secondary endpoint.
CLL, the most common type of leukemia in adults, involves the overproduction of white blood cells and is expected to affect an increasing number of patients. The disease is incurable, but patients often live with it for many years, requiring ongoing treatment, which highlights the importance of effective and tolerable treatment regimens.
Jennifer R. Brown, MD, PhD, the principal investigator of the trial, stated that the AMPLIFY results could represent an important advancement for CLL treatments, as fixed-duration regimens may decrease long-term side effects and drug resistance while improving patients' quality of life.
Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, expressed that the trial's findings underscore the potential benefits of including a BTK inhibitor in fixed-duration treatments. She also suggested that, pending approval, CALQUENCE could offer a new treatment option for CLL patients.
The trial's safety outcomes were consistent with the known profiles of the medicines involved, with low rates of cardiac toxicity and no new safety concerns identified.
AstraZeneca plans to present the detailed data at an upcoming medical meeting and will discuss the findings with global regulatory authorities.
CALQUENCE is currently approved for treating adult patients with mantle cell lymphoma who have received at least one prior therapy and for CLL or small lymphocytic lymphoma. Its approval for the former indication is under accelerated approval based on the overall response rate, with continued approval contingent on verification and description of clinical benefit in confirmatory trials.
This report is based on a press release statement from AstraZeneca.
In other recent news, AstraZeneca has been making significant strides in both its financial performance and clinical trials. The company reported an 18% increase in total revenue, rising to nearly $13 billion in the second quarter, with a core operating profit of $8.4 billion. The firm's revised full-year guidance now anticipates mid-teens percentage increases in both total revenue and core EPS.
In the realm of clinical trials, AstraZeneca announced positive results from its Phase III AMPLIFY trial, demonstrating that its drug Calquence, when used in combination with venetoclax, significantly improved progression-free survival in patients with first-line chronic lymphocytic leukemia. The company's drug Imfinzi also showed potential for treating resectable non-small cell lung cancer, based on positive results from the AEGEAN Phase III trial.
Furthermore, the company's strategic focus includes over 40 phase 3 trials expected to report before the end of 2025, aligning with their 2030 goals of achieving $80 billion in total revenue and launching at least 20 new medicines. These recent developments underscore AstraZeneca's ongoing commitment to advancing in both financial growth and medical innovation.
InvestingPro Insights
AstraZeneca's recent announcement concerning the positive trial results of its drug CALQUENCE® in treating chronic lymphocytic leukemia is a promising development for the company and its stakeholders. The potential expansion of CALQUENCE's indications could have significant implications for the company's financial health and market position.
According to InvestingPro data, AstraZeneca (AZN) currently boasts a substantial market capitalization of 246.35 billion USD, reflecting investor confidence and the company's size within the pharmaceutical industry.
The company's Price/Earnings (P/E) ratio stands at a high 38.21, suggesting that investors are expecting high earnings growth, albeit the company is trading at a high earnings multiple relative to near-term earnings growth. This is further supported by a Price/Book (P/B) ratio of 6.25, indicating that the stock may be valued highly in terms of its net asset value.
In terms of financial performance, AstraZeneca's revenue growth over the last twelve months as of Q2 2024 was 10.45%, with a quarterly revenue growth of 13.33% in Q2 2024. These figures demonstrate the company's ability to increase its earnings over time, which is a positive sign for potential investors.
Furthermore, two InvestingPro Tips relevant to AstraZeneca's situation are:
1) Net income is expected to grow this year, which aligns with the company's promising trial results that could lead to increased product sales and market share; and
2) The company has maintained dividend payments for 32 consecutive years, showcasing its commitment to providing shareholder value and financial stability.
For investors interested in a deeper analysis of AstraZeneca and additional insights, there are 14 more InvestingPro Tips available at InvestingPro. These tips can provide a more comprehensive understanding of the company's financial health and market potential. Use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription to gain access to these valuable insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.